Key Points
- Fairmount Funds Management LLC sold 1,750,000 shares of Apogee Therapeutics at an average price of $76.30 on Jan. 22, a transaction totaling $133,525,000 and reducing its stake by 85.42% to 298,647 shares (≈$22.79M).
- APGE shares opened at $79.86 and were down about 2.5% after the filing; the company has a market cap of $5.46B, a negative PE of -18.23, and a 52‑week range of $26.20–$84.56 (50/200‑day SMAs: $75.01 / $54.10).
- Analysts have a consensus rating of Moderate Buy with an average price target of $105.45 (breakdown: 3 Strong Buy, 7 Buy, 3 Hold, 1 Sell).
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) Director Fairmount Funds Management Llc sold 1,750,000 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the transaction, the director directly owned 298,647 shares of the company's stock, valued at approximately $22,786,766.10. This trade represents a 85.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Apogee Therapeutics Stock Down 2.5%
APGE stock opened at $79.86 on Friday. The stock has a market cap of $5.46 billion, a PE ratio of -18.23 and a beta of 1.41. The firm's 50-day simple moving average is $75.01 and its 200 day simple moving average is $54.10. Apogee Therapeutics Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $84.56.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. Equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts recently commented on APGE shares. Weiss Ratings restated a "sell (d-)" rating on shares of Apogee Therapeutics in a research report on Wednesday. Stifel Nicolaus set a $133.00 price target on Apogee Therapeutics in a research note on Tuesday, January 6th. Wolfe Research started coverage on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. They set a "peer perform" rating on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a "buy" rating and a $103.00 target price for the company. Finally, UBS Group upgraded shares of Apogee Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 7th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Apogee Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $105.45.
Get Our Latest Analysis on Apogee Therapeutics
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of APGE. Nisa Investment Advisors LLC raised its position in Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock worth $33,000 after acquiring an additional 383 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in shares of Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock worth $33,000 after purchasing an additional 246 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock worth $77,000 after purchasing an additional 272 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Apogee Therapeutics during the third quarter valued at approximately $96,000. Finally, BNP Paribas Financial Markets boosted its holdings in Apogee Therapeutics by 34.7% during the second quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company's stock worth $158,000 after buying an additional 941 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
